Truist Securities Maintains Buy on Cytokinetics, Lowers Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Cytokinetics (NASDAQ:CYTK) but lowered the price target from $86 to $70.
May 29, 2024 | 12:53 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities has maintained its Buy rating on Cytokinetics but lowered the price target from $86 to $70, indicating a more cautious outlook.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates a more cautious outlook, likely due to revised expectations or market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100